This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here
BETMIGA™ (mirabegron) logo

BetmigaTM (mirabegron) is indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome and for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to <18 years.1

The prevalence of OAB in men varies by region and age, with a global prevalence estimate of 16%2

When treating male patients with lower urinary tract symptoms (LUTS), keep in mind that men with benign prostatic hyperplasia (BPH) may also experience OAB symptoms.4

OAB in men is often linked to other urological conditions, such as benign prostatic enlargement or obstruction, neurogenic bladder or complications from prostate cancer treatment3



 

Men with LUTS often present with a combination of symptoms4

Combination of Storage and Voiding Symptoms
Combination of Storage and Voiding Symptoms

Post-micturition symptoms in combination with other symptoms are included in the percentages. Figure adapted from Sexton CC, et al. 2009.4

Voiding symptoms vs Storage symptoms
Voiding symptoms vs Storage symptoms

OAB symptoms in men with BPH can be treated with BETMIGA.5,6

References

1.BETMIGA (mirabegron) prolonged-release tablets. Summary of Product Characteristics 2. Zhang L. et al. Int Urogynecology J. 2025;36:1547–1566 3. Blaivas, JG. et al. J Urol. 2009;182(6):2814-7 4. Sexton CC et al. EpiLUTS. BJU International. 2009 Apr;103:12–23. 5. Kakizaki H et al. European urology focus. 2020 Jul 1;6(4):729–37. 6. Kaplan SA et al. (PLUS). 2020 Jan 2;203(6):1163–71.

Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ieor Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.

MAT-IE-BET-2026-00017 Sep 2026